Jörn M Schattenberg, MD, FAASLD
Hepatology — University Medical Center of the Johannes Gutenberg University Mainz, Germany
Jörn M Schattenberg
LeadR Profile
Hepatology
Subspecialties: Gastroenterology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2004 - 2026
Number : 727
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Fibrosis-4 index and cardiac remodelling in the general population: The STANISLAS and African-PREDICT cohorts. fibrosis | Am J Prev Cardiol | 2026 | 0 |
| Risk of metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis: a large-scale study from the Middle East. liver diseases, fibrosis, liver, obesity, risk factors | Int J Obes (Lond) | 2026 | 0 |
| Hearing loss and executive functions - results from a population-based cohort study. cohort studies, perception, ear, executive function, hearing, air, audiometry, hearing loss, audiometry, pure-tone, speech | PLoS One | 2026 | 0 |
| Validated early detection metrics reduce the population requiring liver fibrosis screening. epidemiology, fibrosis, liver, prevalence | Gastroenterology | 2026 | 4 |
| Propelling MASLD trials into the era of non-invasive tests. liver diseases | Lancet Gastroenterol Hepatol Top journal | 2026 | 1 |
Clinical Studies 35
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 70 years with alcohol related liver disease 2024-511596-15-00 — liver diseases, safety, liver, aged | Phase 2 | Recruiting | 2024 |
| Essentiale liquid once daily Phase III study 2025-521678-32-00 — liver diseases, non-alcoholic fatty liver disease, liver diseases, alcoholic, multiple chronic conditions, liver, alcoholics, capsules, hepatitis b, hepatitis | Phase 3 | Active not recruiting | 2026 |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes) 2025-522674-36-00 — liver diseases, liver | Phase 3 | Recruiting | 2026 |
| Time restricted Feeding in MASLD NCT07530809 — liver diseases, clinical protocols, fasting, life style, eating, liver, diet, energy intake, therapeutics, diet, healthy, intermittent fasting | N/A | Recruiting | 2025 |
| Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real life Setting NCT07549607 — liver cirrhosis, biliary | N/A | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map